Table 3.
Inhibition of membrane fusion.
| Target protein | Targeted domain | Name | Virus tested | Sequence derived from | Sequence | Ref (preprint) |
|---|---|---|---|---|---|---|
| Spike S2 | HR1 | 229E-HR2P | 229E-CoV | HR2 (1053–1102) (229E) | VVEQYNQTILNLTSEISTLENKSAELNYTVQKLQTLIDNINSTLVDLKWL | Xia et al., 2018 [132] |
| HR2 | MERS-5HB | MERS-CoV | HR1 + HR2 (3× HR1 residues 984 to 1062 and 2× of HR2 residues 1245 to 1289) (MERS) | HR1–SGGRGG–HR2–GGSGGSGG–HR1–SGGRGG–HR2–GGSGGSGG–HR1 | Sun et al., 2017 [135] | |
| HR1 | P1 | MERS-CoV | HR2 (I1246 to L1286) (MERS) | LTQINTTLLDLTYEMLSLQQVVKALNESYIDLKEL | Gao et al., 2013 [136] | |
| HR1 | HR2P | MERS-CoV | HR2 (1251–1286) (MERS) | SLTQINTTLLDLTYEMLSLQQVVKALNESYIDLKEL | Lu et al., 2014 [137] | |
| HR1 | CP-1 | SARS-CoV-1 | HR2 (1153–1189) (SARS-CoV-1) | GINASVVNIQKEIDRLNEVAKNLNESLIDLQELGKYE | Liu et al., 2004 [134] | |
| HR1 | HR2-8 (HR peptide) | SARS-CoV-1 | HR2 (1126–1193) (SARS-CoV-1) | ELDSFKEELDKYFKNHTSPDVDLGDISGINASVVNIQKEIDRLNEVAKNLNESLIDLQELGKYEQYIK | Bosch et al., 2004 [133] | |
| HR2 | HR1-1 | SARS-CoV-1 | HR1 (889–926) (SARS-CoV-1) | NGIGVTQNVLYENQKQIANQFNKAISQIQESLTTTSTA | Yuan et al., 2004 [138] | |
| HR1 | HR2-18 | HR2 (1161–1187) (SARS-CoV-1) | IQKEIDRLNEVAKNLNESLIDLQELGK | |||
| HR1 | HR2 peptide | SARS-CoV-1 | HR2 (1149–1186) (SARS-CoV-1) | GDISGINASVVNIQKEIDRLNEVAKNLNESLIDLQELG | Zhu et al., 2004 [139] | |
| HR2 | HR1-a | SARS-CoV-1 | HR1 (899–926) (SARS-CoV-1) | YENQKQI ANQFNKA ISQIQES LTTTSTA | Chu et al., 2008 [140] | |
| HR1 | GST-removed-HR2 | HR2 (1145–1192) (SARS-CoV-1) | DVDLGD ISGINAS VVNIQKE IDRLNEV AKNLNES LIDLQEL GKYEQYI | |||
| HR1 | HR2 | HR2 (1151–1185) (SARS-CoV-1) | ISGINAS VVNIQKE IDRLNEV AKNLNES LIDLQEL | |||
| HR1 | EK1 | SARS-CoV-2, SARS-CoV-1, 229E, NL63, OC43 | HR2 (OC43) | SLDQINVTFLDLEYEMKKLEEAIKKLEESYIDLKEL | Xia et al., 2019 [47,141] | |
| HR1 | 2019-nCoV-HR2P | SARS-CoV-2 | HR2 (1150–1185) (SARS-CoV-2) | DISGINASVVNIQKEIDRLNEVAKNLNESLIDLQEL | Xia et al., 2020 [46] | |
| HR1 | [SARSHRC-PEG4]2-chol | SARS-CoV-2 | HR2 (1168–1203) (SARS-CoV-2) | [DISGINASWNIQKEIDRLNEVAKNLNESLIDLQEL -PEG4]2-chol | de Vries1 et al., (preprint) [146] | |
| HR1 | EK1-C4 | SARS-CoV-2, SARS-CoV-1, 229E, NL63, OC43 | HR2 (OC43) | Ac-SLDQINVTFLDLEYEMKKLEEAIKKLEESYIDLKELGSGSG-amino-PEG3-acetyl-Cys(cholesteryloxycarbonylmethyl)-NH acetate salt | Xia et al., 2020 [47] | |
| HR1 | IPB01-IPB-09 | SARS-CoV-2, SARS-CoV-1, 229E, NL63, OC43 | HR2 (1151–1186) (SARS-CoV-2) | IBP02: ISGINASVVNIQKEIDRLNEVAKNLNESLIDLQELK(Chol) | Zhu et al., 2020 [145] | |
| HR2 | P9 | SARS-CoV-1 | HR1 (890–909) (SARS-CoV-1) | GIGVT(A)QNVLYENQKQIANQF | Zheng et al., 2005 [56] | |
| HR1 | P10 | SARS-CoV-1 | HR1 (1161–1180) (SARS-CoV-1) | IQK(E)EIDRLNEVAKNLNESLI | ||
| HR1 + Hrloops | SARSWW-III | SARS-CoV-1 | SARS-CoV-1 hydrophobic S2 | GYHLMSFPQAAPHGVVFLHVTW | Sainz et al., 2006 [148] | |
| SARSWW-IV | GVFVFNGTSWFITQRNFFS | |||||
| SARSWW-V | AACEVAKNLNESLIDLQELGKYE-QYIKW | |||||
| FP region | SARSWW-I | MWKTPTLKYFGGFNFSQIL | ||||
| SARSWW-II | ATAGWTFGAGAALQIPFAMQMAY |